S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

$3.36
-0.06 (-1.76%)
(As of 02/26/2024 ET)
Today's Range
$3.27
$3.40
50-Day Range
$3.27
$4.66
52-Week Range
$2.22
$5.51
Volume
21,590 shs
Average Volume
25,383 shs
Market Capitalization
$175.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
376.4% Upside
$16.00 Price Target
Short Interest
Bearish
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Inventiva in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.39) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

548th out of 942 stocks

Pharmaceutical Preparations Industry

240th out of 415 stocks


IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

Inventiva (NASDAQ:IVA) PT Lowered to $25.00
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Inventiva SA ADR IVA
Analysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)
Inventiva reports 9M results
Inventiva Share Price (IVA.PA)
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/26/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
117
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$25.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+376.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.83 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,439,000
Market Cap
$175.05 million
Optionable
Not Optionable
Beta
0.93

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 58)
    Co-Founder, CEO & Chairman
    Comp: $544.97k
  • Dr. Pierre Broqua Ph.D. (Age 62)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $408.76k
  • Mr. Jean Volatier (Age 59)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 50)
    General Counsel
  • Ms. Nathalie Harroy (Age 57)
    Head of Human Resources
  • Dr. Michael Cooreman (Age 66)
    Chief Medical Officer














IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

8 equities research analysts have issued 1 year price objectives for Inventiva's shares. Their IVA share price targets range from $11.00 to $25.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 376.4% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2024?

Inventiva's stock was trading at $4.52 at the start of the year. Since then, IVA shares have decreased by 25.7% and is now trading at $3.3585.
View the best growth stocks for 2024 here
.

Are investors shorting Inventiva?

Inventiva saw a increase in short interest in January. As of January 31st, there was short interest totaling 88,500 shares, an increase of 8.3% from the January 15th total of 81,700 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 8.3 days.
View Inventiva's Short Interest
.

When is Inventiva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our IVA earnings forecast
.

When did Inventiva IPO?

(IVA) raised $103 million in an IPO on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 2/27/2024 by MarketBeat.com Staff